A5036992985- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Gastrointestinal Tumor Research and Treatment
- Soft tissue tumor case studies
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Gastrointestinal motility and disorders
- Management of metastatic bone disease
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Metastasis and carcinoma case studies
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Urological Disorders and Treatments
- Bladder and Urothelial Cancer Treatments
- Acute Myeloid Leukemia Research
- Computational Drug Discovery Methods
- Lung Cancer Treatments and Mutations
- Neurofibromatosis and Schwannoma Cases
- Helicobacter pylori-related gastroenterology studies
Clatterbridge Cancer Centre NHS Foundation Trust
2013-2023
East and North Hertfordshire NHS Trust
2007
Lister Hospital
2007
BackgroundFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as sarcoma.MethodsThe GeDDiS trial was a randomised controlled phase 3 done in 24 UK hospitals one Swiss Group Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed of Trojani grade 2 3, disease progression before enrolment, no previous chemotherapy any cancer. Patients...
BackgroundThe interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction progression-free survival allocated to cetuximab plus chemotherapy compared those given alone. The focus present was assess effect on overall survival.MethodsNew multicentre, open-label, randomised, controlled, phase 3 trial. Adult (aged ≥18 years) KRAS wild-type (codons 12, 13, and 61) or suboptimally metastases WHO performance status 0–2...
Successful colonoscopy preparation requires a method which is easy to administer. Simplifying this technique would be useful for adult and pediatric gastroenterologists. Most cleanout agents are not well tolerated by children. Polyethylene glycol without electrolytes (PEG3350 electrolytes) has been used constipation bowel cleanout, but studied as 2-day in This study evaluates the dosing, effectiveness satisfaction with PEG3350 Parents of patients aged 5 years or older undergoing...
Abstract Background Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. Methods Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-centre, phase II trial of continuous axitinib treatment patients ≥16 years, performance status ≤2, pathologically-confirmed advanced/metastatic soft tissue sarcoma (STS). Patients were recruited within four tumour strata, each analysed separately:...
11006 Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of gastrointestinal tract. Advanced GIST treated with tyrosine kinase inhibitors (TKIs). Most patients (pts) develop resistance over time. We reported in 2013 (Van Looy CTOS) that cabozantinib (cabo), a TKI targeting KIT/MET/AXL/VEGFR, showed activity xenograft models through inhibition growth, proliferation and angiogenesis, both imatinib-sensitive -resistant tumors (Gebreyohannes Mol Cancer...
Treatment options for patients with unresectable and/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. New drugs required.To assess whether cabazitaxel demonstrated sufficient antitumor activity in or inoperable locally advanced DDLPS to justify further investigation a phase 3 setting.This international multicenter, open-label single-arm 2 trial was conducted at 10 institutions 4 European countries from March 2015 2019. Eligible had have histologically proven evidence of...
A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared alone. The recently presented III study and sarcoma was discordant this finding.We performed a retrospective analysis adult advanced-/metastatic STS treated at least two cycles eight units across England Northern Ireland between May 2017 March 2019.172 were evaluable 40 (23.3%) had died time...
11518 Background: Treatment options for patients with unresectable and/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. The most effective agents include doxorubicin, ifosfamide, trabectedin and eribulin, but, in general, objective response rates (ORR) progression free survival (PFS) modest. Cabazitaxel exerts its effect through inhibition of microtubular disassembly has been shown to be relatively safe, well-tolerated. EORTC 1202 assessed whether cabazitaxel demonstrated...
10568 Background: N, a tumor-targeted antivascular agent, displays biphasic dose response curve with activity shown at low (LD) or high (HD). Vascular effects involve LD an early vessel stabilization that enhances intratumor D uptake followed by late damage and HD rapid disruption. Methods: STS patients (pts), stratified prior (> vs ≤ 300 mg/m 2 ), were randomized to N alone given (0.8 μg/m ) in arm A (45 /d1/q1w) B, combined (60 /d1/q3w/6 cycles) C D. Primary aim of this 4-arm phase II...
Trabectedin is a chemotherapeutic used to treat advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Although it associated with low incidence of cardiotoxicity, when this occurs can be fatal or significantly compromise the quality life in patients Here, we present series 4 cases where trabectedin-treated developed cardiovascular complications. Similar previous literature describing association, all had prior treatment anthracyclines presented at different time points...
10525 Background: NGR-hTNF, a tumor targeted antivascular agent, exhibits biphasic dose-response curve with activity shown at low dose (LD) or high (HD). Vascular effects LD are driven by early vessel normalization that enhances intratumoral doxorubicin (D) uptake and late damage, while HD rapid disruption. Methods: Advanced STS patients (pts), stratified prior D (> ≤ 300 mg/m2), were randomly assigned to receive NGR-hTNF alone (0.8 μg/m2/d1/q1w) in arm A (45 B, (60 mg/m2/d1/q3w) C D....
Aggressive abdominal wall fibromatosis is an uncommon tumour that has propensity for significant growth. Patients often present during pregnancy, with growth related to the associated hormonal changes having been described.[1][1] In majority of patients condition can be managed
11556 Background: The optimal treatment for patients with advanced dedifferentiated (DD) liposarcoma (LPS) remains uncertain. Single agents which are most effective include doxorubicin and ifosfamide but, as soft tissue sarcomas (STS) in general, objective response rates (ORR) progression free survival (PFS) very modest. Cabazitaxel exerts its effect through inhibition of microtubular disassembly has been shown to be relatively safe, well-tolerated. EORTC 1202 assessed whether cabazitaxel...